Treatment of Multiple Myeloma with All-Trans Retinoic Acid Alone and in Combination with Chemotherapy: a Phase I/II Trial

References

• Ogata, A., Nishimoto, N., Shima, Y., Yosltizaki, K. and Kishimoto, T. (1994) "Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction", Blood, 84, 3040— 3046.
   Google Scholar
• Palumbo, A., Battaglio, S., Napoli, P., Bruno, B., Omede, P., Boccadoro, M., et al. (1995) "Retinoic acid inhibits the growth of human myeloma cells in vitro", British Journal of Haematology, 89, 555— 560.
   PubMed Web of Science ®Google Scholar
• Pulkki, K., Neva, M., Koskela, K., 011ikainen, H., Remes, K. and Pelliniemi, T.-T. (1995) "IL-6-receptor-mediated growth inhibition by all-trans retinoic acid but not by interferon-a in human myeloma cells", Annals of New York Academy of Sciences, 762, 457–458.
   PubMed Web of Science ®Google Scholar
• Sidell, N., Taga, T., Hirano, T., Kishimoto, T. and Saxon, A. (1991) "Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors", The Journal of Immunology, 146, 3809 — 3814.
   Google Scholar
• Smith, MR., Xie, T., Joshi, I. and Schilder, R.J. (1998) "Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells", British Journal of Haematology, 102, 1090— 1097.
   Google Scholar
• Chen, Y., Desai, P., Shiao, R., Lavelle, D., Haleem, A. and Chen, J. (1996) "Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid:synergy through modulation of interleukin-6 autocrine loop at multiple sites", Blood, 87, 314 — 323.
   Google Scholar
• Tosi, P., Pellacani, A., Visani, G., Ottaviani, E., Ronconi, S., Zamagni, E., et al. (1999) "In vitro treatment with retinoids decreases bc-2 protein expression and enhances dexamethasone-induced cytotocity and apoptosis in multiple myeloma cells", European Journal of Haematology, 62, 143— 148.
   Google Scholar
• Vesole, D., Kornbluth, J., Jagannath, S., Sznol, M., Mattox, S., Vaught, L., et al. (1993) "Biological response modifiers in refractory multiple myeloma: lack of clinical efficacy of recombinant human interleukin-4 and all-trans retinoic acid", Blood, 82\(suppl. 1), 263a.
   Google Scholar
• Niesvizky, R., Siegel, D.S., Busquets, X., Nichols, G., Muindi, J., Warrell, R.P.J., et al. (1995) "Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma", British Journal of Haematology, 89, 217 —218.
   Google Scholar
• Musto, P., Falcone, A., Sajeva, MR., D'Arena, G., Bonini, A. and Carotenuto, M. (1995) "All-trans retinoic acid for advanced multiple myeloma", Blood, 85, 3769 — 3770.
   Google Scholar
• Hussein, MA., Bocock, K., Bloom, T., Finke, J., Rybicki, L., Scott, R., et al. (1998) "Biologic and clinical evaluation of high intermittent dose all trans retinoic acid (ATRA) in refractory multiple myeloma patients", Blood, 92, 108a
   Google Scholar
• Dune, B.G.M. and Salmon, S.E. (1975) "A clinical staging system for multiple myeloma", Cancer, 36, 842–854.
   Google Scholar
• Adamson, P.C., Boylan, J.F., Balis, F.M., Murphy, R.F., Godwin, K.A., Gudas, Li., et al. (1993) "Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein", Cancer Research, 53, 472 — 476.
   Google Scholar
• Lefebvre, P., Thomas, G., Gourmel, B., Agadir, A., Castaigne, S., Dreux, C., et al. (1991) "Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia", Leukemia, 5, 1054 — 1058.
   Google Scholar
• Klein, B., Zhang, X., Lu, Z. and Bataille, R. (1995) "Interleukin-6 in human multiple myeloma", Blood, 85, 863–872.
   PubMed Web of Science ®Google Scholar
• Zhang, X., Klein, B. and Bataille, R. (1989) "Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma", Blood, 74, 11 — 13.
   Google Scholar
• Labaume, S., Chopin, M., Pla, M. and Brouet, J.C. (1998) "Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells", Leukemia and Lymphoma, 30, 361–366.
   Google Scholar
• Okamura, T., Masuda, M., Arai, Y., Ishida, C., Shudou, K. and Mizoguchi, H. (1998) "All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combina-tion with anti-Fas monoclonal antibody in the human myeloma cell line, U266B1", Experimental Hematology, 26, 501 —506.
   Google Scholar
• Joseph, B., Lefebvre, O., Méreau-Richard, C., Danzé, P., Belin-Plancot, M. and Formstecher, P. (1998) "Evidence for the involvement of both retinoic acid receptor- and retinoic X receptor-dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RPMI 8226", Blood, 91, 2423–2432.
   PubMed Web of Science ®Google Scholar
• Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", The New England Journal of Medicine, 341, 1565 — 1571.
   PubMed Web of Science ®Google Scholar
• Raje, N. and Anderson, K.C. (1999) "Thalidomide—A revival story", The New England Journal of Medicine, 341, 1606 — 1609.
   Web of Science ®Google Scholar
• Oikawa, T., Hirotani, K., Nakamura, O., Shudo, K., Hiragun, A. and Iwaguchi, T. (1989) "A highly potent antiangiogenic activity of retinoids", Cancer Letters, 48, 157— 162.
   Google Scholar
• Weber, D.M., Bseiso, A., Wood, A., Gavino, M. and Alexanian, R. (1997) "All-trans retinoic acid for multiple myeloma", Blood, 90\(suppl. 1), 357a.
   Google Scholar
• Musto, P., Sajeva, MR., Sanpaolo, G., D'Arena, G., Scalzulli, P.R. and Carotenuto, M. (1997) "All-trans retinoic acid in combination with a-interferon and dexamethasone for advanced multiple myeloma", Haematologica, 82, 354— 356.
   Google Scholar
• Bataille, R., Chappard, D. and Klein, B. (1992) "Mechanisms of bone lesions in multiple myeloma", Hematology/Oncology Clinics of North America, 6, 285–295.
   PubMed Web of Science ®Google Scholar
• Koskela, K., Pelliniemi, T-T., Remes, K., Rajamäki, A. and Pulkki, K. (1997) "Serum oncostatin M in multiple myeloma: association with prognostic factors", British Journal of Haematology, 96, 158 — 160.
   Google Scholar
• Wierzbowska, A., Urbanska-Rys, H. and Robak, T. (1999) "Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma", British Journal of Haematology, 105, 412–419.
   PubMed Web of Science ®Google Scholar
• Koskela, K., Pelliniemi, T.-T., Rajamäki, A., Pulkki, K. and Remes, K. (2000) "Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis", European Journal of Haematology, 65, 52–56.
   PubMed Web of Science ®Google Scholar
• Adamson, P.C. (1994) "Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia", Seminars in Hematology, 31, 14 — 17.
   PubMed Web of Science ®Google Scholar